| |
CD4 < 200 (N = 17)
|
CD4 > 200 (N = 17)
|
P value
|
|---|
|
Mean age (years)
|
50 ± 9
|
47 ± 7
|
0.2619
|
|
Weight (kg)
|
54.71 ± 9.71
|
58.18 ± 8.63
|
0.1895
|
|
BMI (kg/m2)
|
21.19 ± 3.52
|
21.69 ± 2.92
|
0.4691
|
|
Time on ART (years)
|
7 ± 3
|
9 ± 2
|
0.0951
|
|
Gender, N (%)
|
|
Male
|
7 (41.2)
|
8 (47.1)
|
> 0.9999
|
|
Female
|
10 (50.0)
|
9 (52.9)
|
|
Ethnicity, N (%)
|
|
Han
|
4 (23.5)
|
4 (23.5)
|
> 0.9999
|
|
Other minorities
|
13 (58.8)
|
13 (76.5)
|
|
Acquisition of HIV, N (%)
|
|
Injection drug use
|
3 (17.6)
|
1 (5.9)
|
0.7309
|
|
Sexual route
|
12 (70.6)
|
14 (82.3)
|
|
Unknown
|
2 (11.8)
|
2 (11.8)
|
|
T cells (cells/μL)
|
|
CD4+ T cell counts before ART
|
159 ± 143
|
210 ± 149
|
0.1425
|
|
CD3+ T cell counts
|
642 ± 263
|
764 ± 178
|
0.0518
|
|
CD4+ T cell counts
|
149 ± 38
|
266 ± 57
|
< 0.0001*
|
|
CD8+ T cell counts
|
448 ± 233
|
454 ± 171
|
0.4902
|
|
CD4/CD8 ratio
|
0.40 ± 0.20
|
0.72 ± 0.45
|
0.0033*
|
|
Nadir CD4+ T cell counts
|
144 ± 37
|
239 ± 36
|
< 0.0001*
|
|
ART regimens, N (%)
|
|
NRTI + NNRTI
|
13 (76.5)
|
17 (100)
|
0.1026
|
|
NRTI + PI
|
4 (23.5)
|
0 (0)
|
|
3TC + AZT + EFV
|
4 (23.5)
|
5 (29.4)
|
0.1404
|
|
3TC + AZT + NVP
|
3 (17.6)
|
6 (35.3)
|
|
3TC + TDF + EFV
|
5 (29.4)
|
5 (29.4)
|
|
3TC + AZT + LPV
|
2 (11.8)
|
0 (0)
|
|
3TC + TDF + NVP
|
1 (5.9)
|
1 (5.9)
|
|
TDF + AZT + LPV
|
1 (5.9)
|
0 (0)
|
|
3TC + LPV
|
1 (5.9)
|
0 (0)
|
- Data are presented as Mean ± SD unless otherwise indicated. P values were calculated using Mann–Whitney test. Red marked lines represent P < 0.05. BMI body mass index, HIV human immunodeficiency virus, ART antiretroviral therapy, NRTI nucleoside reverse transcriptase inhibitor, NNRTI non-nucleoside reverse transcriptase inhibitor, PI protease inhibitor, 3TC lamivudine, AZT zidovudine, EFV efavurebz, NVP nevirapine, TDF tenofovir, LPV lopinavir
- *P < 0.05
